BI's Pradaxa set to replace warfarin in Scotland?
This article was originally published in Scrip
Scotland's health technology assessment body, the Scottish Medicines Consortium, has okayed Boehringer Ingelheim's blood thinning drug Pradaxa (dabigatran etexilate) for preventing stroke and systemic embolism in adults with atrial fibrillation for use on the Scottish NHS.
You may also be interested in...
The R&D-based lobby group, Medicines Australia, has published a report calling for stakeholders across the Australian healthcare ecosystem to discuss how to “pragmatically address the evidence needs of the future.”
NICE will review new data in deciding whether to ok the use of Spinraza in non-ambulant SMA type III patients.
WTO member states including the EU, the US and the UK argue that waiving certain IP rights is unnecessary for enhancing responses to the Covid-19 pandemic.